News Releases

Forty Seven Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference

August 2, 2018 at 8:00 AM EDT

MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer, will present a company overview and participate in a moderated panel, “Immuno-Oncology: The Quest for a Cure,” at the 38th Annual Canaccord Genuity Growth Conference on Thursday, August 9, 2018 in Boston, MA. The corporate presentation will begin at 11:30 a.m. ET and the panel discussion will begin at 12:00 p.m. ET.

Live webcasts of the presentation and panel discussion will be available under “Events & Presentations” in the Investors section of the Company’s website at Replays of the webcasts will be available on the Forty Seven website for 90 days following the event.

About Forty Seven Inc.:
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven’s lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin’s lymphoma and colorectal carcinoma.

For more information please visit or contact

For journalist enquiries please contact Ryan Ferrell at or phone (312) 506-5202.

For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at or phone (212) 362-1200.

Primary Logo

Source: Forty Seven, Inc.

Email Alerts
Contact IR
Investor FAQs
RSS Feeds